A role of MRI-Ultrasound fusion targeted biopsy of prostate in the diagnosis of prostate cancer


DOI: https://dx.doi.org/10.18565/urology.2019.16.73-77

O.Yu. Shestopalova, A.A. Jakovenko, A. Sh. Rumyant­sev, А.V. Matveev, E.S. Nevirovich

Pavlov First Saint Petersburg State Medical University of the Ministry of Health of Russia, Saint Petersburg, Russia
Aim. To compare the results of the MRI-ultrasound fusion targeted biopsy (MRF-TB) and systematic 12-core biopsy (SB) of the prostate and analyze the relationship between biopsy results and the prebiopsy multiparametric MRI.
Material and methods. The study included 380 men aged from 45 to 80 years with a total PSA level of 4 to 10 ng/ml (according to Hybritech calibration) and a negative result of digital rectal examination. All men underwent the multiparametric MRI of the prostate before biopsy. MRI results were assessed according to the PI-RADS Version 2 criterion. In all men (n=247) with PI-RADS category 2 or higher lesion were performed MRF-TB (4 targeted columns) and SB (12 standard points) of the prostate.
Results. There were no significant differences in the detection of all types of prostate cancer (PCa) in all patients between MRF-TB and SB (p=0.731). At the same time, significantly less low-risk PCa (Gleason 6) (p<0.001) and significantly more aggressive PCa (Gleason ≥ 7) (p<0.001) were detected in MRF-TB group in comparison with SB group. In addition, MRF-TB allowed to detect significantly more aggressive type of PCa (Gleason ≥ 4 + 3) compared to SB (p=0.025).
Conclusion. MRF-TB allows to detect more significant PCa (Gleason ≥ 7) in comparison with SB, while limiting the detection of low-risk PCa (Gleason 6) in general population of men.

Similar Articles


Бионика Медиа